Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials

Eric McDade

doi:10.1111/jgs.15829

Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials

Eric McDade

Hope Center for Neurological Disorders

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Original language	English
Pages (from-to)	845-847
Number of pages	3
Journal	Journal of the American Geriatrics Society
Volume	67
Issue number	4
DOIs	https://doi.org/10.1111/jgs.15829
State	Published - Apr 2019

Access to Document

10.1111/jgs.15829

Cite this

@article{9ea16f4265284165b55e8e8e6f1c02e6,

title = "Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials",

author = "Eric McDade",

note = "Funding Information: Financial Disclosures: Eli Lilly: Continuing Medical Education–sponsored Speaker's Bureau. Eli Lilly: Data Safety Monitoring Board member. Eli Lilly: Trial cosponsor (solanezumab), no personal salary. Roche: Trial cosponsor (gantenerumab), no personal salary. Conflict of Interest: Dr McDade has received personal compensation from Eli Lilly for Continuing Medical Education and Advisory Board roles. He receives institutional support for clinical trials from Eli Lilly and Roche. Author Contributions: Dr McDade was responsible for the development and preparation of the manuscript. Sponsor's Role: This work represents the personal opinion of Dr McDade, and there was no sponsor involved.",

year = "2019",

month = apr,

doi = "10.1111/jgs.15829",

language = "English",

volume = "67",

pages = "845--847",

journal = "Journal of the American Geriatrics Society",

issn = "0002-8614",

number = "4",

}

TY - JOUR

T1 - Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials

AU - McDade, Eric

N1 - Funding Information: Financial Disclosures: Eli Lilly: Continuing Medical Education–sponsored Speaker's Bureau. Eli Lilly: Data Safety Monitoring Board member. Eli Lilly: Trial cosponsor (solanezumab), no personal salary. Roche: Trial cosponsor (gantenerumab), no personal salary. Conflict of Interest: Dr McDade has received personal compensation from Eli Lilly for Continuing Medical Education and Advisory Board roles. He receives institutional support for clinical trials from Eli Lilly and Roche. Author Contributions: Dr McDade was responsible for the development and preparation of the manuscript. Sponsor's Role: This work represents the personal opinion of Dr McDade, and there was no sponsor involved.

PY - 2019/4

Y1 - 2019/4

UR - http://www.scopus.com/inward/record.url?scp=85062774598&partnerID=8YFLogxK

U2 - 10.1111/jgs.15829

DO - 10.1111/jgs.15829

M3 - Article

C2 - 30851119

AN - SCOPUS:85062774598

SN - 0002-8614

VL - 67

SP - 845

EP - 847

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

IS - 4

ER -

Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials

Access to Document

Other files and links

Cite this